The Cannabis Landscape On A ‘Roll’ In Australia - Latest Updates For Market Enthusiasts

Follow us on Google News:
 The Cannabis Landscape On A ‘Roll’ In Australia - Latest Updates For Market Enthusiasts

Amidst the contemplation on the growth of the medicinal cannabis space in Australia, the legalisation of medicinal cannabis is expected to contribute approximately $8.5 million in the nation’s state and federal tax. The utilisation of this amount towards concepts of health, environment and education is paramount.

With evolving times, where modernisation has taken a toll over taboos like cannabis, the global business is undergoing a massive transition to procure advantages from every sector possible. Cannabis, better expressed as a cannabinoid drug by The Alcohol and Drug Foundation, is the product of the sativa plant which has psychoactive cannabinoid THC and non-psychoactive cannabidiol.

Used for recreational and medicinal purposes, cannabis has been a debatable product since time immemorial. However, with legalisation in Canada, Uruguay, North Korea and Alaska, more countries like Malaysia, Thailand, Singapore and Australia are making significant progress to reap benefits of Cannabis.

Cannabis in the Aussie Land

Australia has made notable progress in the medicinal Cannabis field and took the world by surprise after it joined the bandwagon of the few countries to have legalised medicinal cannabis in the country in February 2016. With this advancement came in a tide of investments, booming businesses, global relations and employment opportunities. But the health sector was the most impacted, and positively. The medicinal cannabis is believed to possess traits that cure critical ailments like Cancer, AIDS, cancer, PTSD, depression, epilepsy and seizures. The list goes on, and research and development are being conducted across medical companies and centres to gain more insight on the subject.

The success and acceptance of the legalisation of medicinal cannabis has broken trivia revolving around the use of cannabis for recreational purposes, which remains to be an illegal act, but is doing a fair round of debates amid public and private agencies of the country.

The Australian cannabis market is expected to have a net worth of approximately $55 million by the end of 2025.

Latest Updates in The Cannabis Space

Undoubtedly, the cannabis market is booming in Australia, and is here to stay. With the stock market welcoming international investors to invest in ‘Pot Stocks’ and the country involving in global trade relations, it is safe to say that Australia is a strong contender in the field of medicinal cannabis.

Let us have a look at the latest buzz in the Cannabis sphere:

Althea Group crosses borders to buy a Canadian cannabis player

Taking the Cannabis baton in its hands is a domestic cannabis player Althea Group (ASX: AGH), which announced its leap into the world’s benchmark and one of the largest cannabis markets, Canada. AGH is in the process of buying a Canadian recreational cannabis company, Peak Processing Solutions, which is focussed on the extraction, production and processing of edibles, drinks and cosmetics imbibed with cannabis.

Estimated Peak Production Capabilities (Source: AGH’s Investor Presentation)

This is an icing on the cake for AGH on a global trade level, as it has recently been granted an import license in the UK and has opened one of the UK’s first cannabis destination clinics (MyAccess Clinics) in London and is most likely to open two more in Q319.

Capital Raising: Moreover, the company is in advanced negotiations for a probable JV to step into the Portugal market and had announced a capital raising worth A$30 million (which would settle on 8 August 2019) to fund the Peak acquisition July 2019, which is expected to be complete in September 2019, and expand current and future growth initiatives.

Use of funds in case the acquisition proceeds (Source: AGH’s report)

June 2019 Quarterly Update: As per its June 2019 Quarterly Activities report, the company had Unaudited sales of $411,663, soared up by 226 per cent on a Q-o-Q basis. 225 Healthcare Professionals had been prescribed with AGH’s medicinal cannabis products, an average increase of 127 per cent on a M-o-M basis. 1,334 patients had been prescribed these products (as of 23 July) with an end of June average M-o-M increase of 144 per cent.

Patients prescribed Althea’s medicinal cannabis products (Source: AGH’s report)

In the UK sphere, AGH Launched Althea Concierge UK for medical education and clinical evidence purposes and received its first patient prescription for medicinal cannabis. AGH had been selected to supply medicinal cannabis with a target of 20,000 patients.

A SAFE Banking Act for Pot Stocks in the coming times?

Banks are into disciplined and stern business. Given the federal illegality clouds hovering in the Cannabis space, banks are often reluctant to work with marjiuana players to save themselves from issues like money laundering. Hence, the cash-only cannabis operations are vulnerable to fall prey to criminal acts. With the steady yet massive growth in the Cannabis sector, which is expected by many experts to generate a profit of more than $22 billion for both the recreational and medical markets by 2022, banks are stepping into the ‘high’ business.

A Secure And Fair Enforcement (SAFE) Banking Act is the latest proposed legislation which is aimed towards the prevention of federal banking regulators from sanctioning banks to link with legal cannabis businesses, while safeguarding criminal acts. The Senate Committee on Banking, Housing and Urban Affairs would hear from the representatives of the cannabis and financial services industries regarding the much-anticipated Act, as market enthusiasts await such developments.

BOD Australia observes notable Cannabis prescription growth

Adding on to the progress report on Australian Cannabis Business is a health products and supplements player, BOD Australia Limited (ASX: BDA), which had a momentous growth of 273 per cent on a M-o-M basis (June-July 2019) in its 5% CBD MediCabilis™ product’s prescriptions volumes. In June and July 2019, 220 prescriptions had been fulfilled, up by 55 per cent when compared from January to May, with repeat prescriptions.

The company expects a sustained growth over coming months, while it pursues international expansion opportunities for the product, which treats pain, stress, anxiety and neurological disorders. The company has witnessed a considerable acceptance through its recent distribution agreement with Burleigh Heads Cannabis and its partner firm, Cannabis Doctors Australia.

Stock Performance: The shares of BDA settled the day’s trading up by 11.61 per cent at A$0.625 on ASX on 25 July 2019.

CropLogic Limited and Shephard Brothers join hands to grow CBD hemp trimmed flower

Amid the traction in the Cannabis market, accoladed firm, farm manger and agtech company CropLogic Limited (ASX: CLI) announced a JV with the Shephard Brothers, who are well-versed Oregonian agriculturalists. As per the JV, the parties would grow premium CBD hemp trimmed flower, which is believed to deliver greater returns than hemp biomass.

CLI would implement its agricultural skill set and agtech over an additional 16.6 acres of premium hemp, which is specially cultivated to grow the trimmed CBD flower. The Shephard Brothers would provide acreage, shedding, labour, machining and storage. The proceeds would be divided equally, and a production in the range of 8,000 and 10,500 lbs of trimmed flower is expected out of the deal.

Stock Performance: CLI settled the day’s trading at A$0.061, down by 1.61 per cent on 25 July 2019.


This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK